Milestone Pharmaceuticals Inc. Common Shares — Rendiconto Finanziario Trimestrale (NASDAQ:MIST) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 252.98 M
Employee 38
Founded 2003
CEO N/A
Website www.milestonepharma.com
Headquarter Quebec, Canada
FIGI BBG009DR4MN8
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

252.98 M Capitalizzazione di mercato

Notizie

Milestone Pharmaceuticals pianifica studio di registro PSVT nel mondo reale

Raymond James avvia la copertura di Milestone Pharmaceuticals con Strong Buy

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Transcript della relazione sugli utili: Milestone Pharmaceuticals raggiunge le previsioni EPS, titolo in calo

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Il trattamento CARDAMYST di Milestone per la TPSV ora disponibile nelle farmacie USA

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

I regolatori europei accettano la domanda per lo spray nasale etripamil per PSVT